NBRV News and Press, Nabriva Therapeutics plc From 07/28/20

- XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years -XENLETA approval provides urgently needed short-course, empiric monotherapy treatment option for CAP aligned with core principles of antimicrobial stewardship DUBLIN, J...

Nabriva Therapeutics (NASDAQ: NBRV ) announces encouraging results from a preclinical study assessing oral antibiotic Xenleta (lefamulin) in a mouse model of lipopolysaccharide (LPS)-induced lung neutrophilia (induced lung inflammation via intranasal administration of LPS). More news...

-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone -Nabriva awarded grant funding from the Austrian Research Promotion Agency to further characterize the anti-inflammatory and immunomodulatory properties of Lefamulin DUBLIN, Ireland, July...

DUBLIN, Ireland, July 16, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sunovion Pharmaceutical...

DENVER, Colo., July 16, 2020- Today’s biotech headlines include developments from Emmaus Life Sciences, Inc. (OTCQB:EMMA), AC Immune SA (NASDAQ:ACIU), and Nabriva Therapeutics plc (NASDAQ:NBRV). Emmaus Life Sciences, Inc. (OTCQB:EMMA), a leader in sickle cell disease treatment, announced ...

Coronavirus Penny Stocks To Watch In July 2020 Want to talk about something crazy? Earlier this year we said “ coronavirus penny stocks ” are “a thing” now. But that was initially a joke at the time. Now 7 months later, COVID-19 has ballooned into something that has...

Analysts Appear Bullish On These Penny Stocks; Where Do You Stand? Looking for penny stocks to buy ? I’m sure you’re not alone and right now you’re probably doing research for the rest of the week. No matter how you slice it, the typical timeframe for trading penny stocks...

Nabriva Therapeutics (NASDAQ: NBRV ) enters into an agreement with subsidiaries of Merck (NYSE: MRK ) granting them exclusive distribution rights to antibiotic Sivextro (tedizolid phosphate) in the U.S. and certain of its territories for the treatment of patients at least 12 years old ...

Accretive transaction creates synergies and scale that strengthen Nabriva’s community-focused commercialization organization to optimize product uptake   Nabriva partners with Amplity Health to provide community-focused customer engagement and sales initiatives for SIVEX...

CymaBay Posts Positive Seladelpar Data for Bile Duct Disorder CymaBay Therapeutics ( CBAY ) reported upbeat data for its open label Phase 2 study of seladelpar for treating patients suffering from primary biliary cholangitis. Seladelpar is a potent and selective peroxisome proliferator-a...